Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.
Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely fractures, is therefore, important for both the individual and society. This review discusses: the goals of PMO prevention; the identification of women at risk, including the use of bone mineral density and bone turnover markers; the relevance in the prevention setting of various current guidelines for PMO management; recent data on therapeutic options for the treatment and prevention of PMO, in particular bisphosphonates, hormone replacement therapy and several other new pharmacological agents. It concludes that it is crucial for PMO prevention to start before disease onset and that, in the light of recent evidence, the existing guidelines need updating if they are to continue to be relevant.
Reginster
J-Y
JY
Unit d'Exploration du Metabolisme de l'Os et due Cartilage, CHU Centre Ville, Liége, Belgium. jyreginster@ulg.ac.be
D045930:Anabolic Agents / Q000627:therapeutic use; D015519:Bone Density / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D011960:Receptors, Estrogen / Q000378:metabolism; D012307:Risk Factors; D014807:Vitamin D / Q000378:metabolism
D045930:Anabolic Agents; D004164:Diphosphonates; D011960:Receptors, Estrogen; D014807:Vitamin D